Navigation Links
Lymphoma Patients Maybe Helped by Adding Radioimmunotherapy to Chemo

CHICAGO, According to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings, patients treated for follicular lymphoma, a slow-growing type of non-Hodgkins lymphoma, may benefit from chemotherapy followed by radioimmunotherapy.

Over 90 percent of study patients responded completely to the treatment and since only a short-course of chemotherapy was used, side effects were limited and well-tolerated. Radioimmunotherapy was delivered through the use of a radiolabeled monoclonal antibody specifically designed to kill lymphoma cells with the help of a radioactive atom.

We found that adding a radioactive monoclonal antibody to standard chemotherapy helped lymphoma patients achieve a higher complete response rate. We hope that this will translate into long-lasting remissions, said Samuel Jacobs, M.D., lead investigator and associate director for clinical investigations at the University of Pittsburgh Cancer Institute and UPMC Cancer Centers.

In the study, a radiolabeled monoclonal antibody called ibritumomab tiuxetan (IT) was added to CHOP-R, a standard multi-drug regimen for follicular lymphoma that consists of cyclophosphamibe, doxorubicin, vincristine, prednisone and rituximab. Investigators reported on 50 patients treated with CHOP-R, examined their responses and then treated them with IT. Sixty-eight percent of the patients had a complete response to treatment with CHOP-R. This percentage increased to 96 percent after treatment with IT.

The complete response rate was determined by both conventional CT and the use of PET, or positron emission tomographya scan that measures abnormal molecular cell activity. PET was used to determine which patients had an early complete disease response after treatment with chemotherapy alone and after treatment with IT. The researche rs found that five out of 16 patients who had a positive PET scan after the initial chemotherapy phase of treatment relapsed. Of the 34 patients whose early PET scans were negative, none have relapsed to-date.

We were surprised to find that PET was a useful tool in determining those patients who were at highest risk for their diseases to relapse. Our next step is to compare the tumor characteristics of the patients who relapsed to those who had an early complete response, said Dr. Jacobs.


'"/>




Related medicine news :

1. Lymphomas Link to Hepatitis C
2. No Lymphoma Risk From Rheumatoid Arthritis Drugs
3. New Guidelines For Assessing Lymphoma Treatment
4. A Novel Treatment for KSHV-infected Lymphomas
5. Risk of Lymphoma Increases With Hepatitis C Virus Infection
6. Study Finds Lymphoma Drug Effective Over Long Term
7. Long-term Oral Steroid Therapy Decreases Lymphoma Risk in Rheumatoid Arthritis
8. One in Three Heart Attack Patients Have No Chest Pains
9. Amphetamines Help Recovery of Stroke Patients
10. Painkillers Do Not Shorten Dying Patients Lives
11. Patients With Filariasis More Prone To HIV Infection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
Breaking Medicine Technology: